Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Assets Average: 2021-2025

Historic Assets Average for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $343.1 million.

  • ARS Pharmaceuticals' Assets Average rose 56.13% to $343.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.1 million, marking a year-over-year increase of 56.13%. This contributed to the annual value of $292.2 million for FY2024, which is 13.55% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Assets Average of $343.1 million as of Q3 2025, which was up 7.10% from $320.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Assets Average high stood at $374.6 million for Q2 2021, and its period low was $187.0 million during Q1 2022.
  • Over the past 3 years, ARS Pharmaceuticals' median Assets Average value was $265.0 million (recorded in 2023), while the average stood at $272.5 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Assets Average dropped by 21.47% in 2022 and then soared by 56.13% in 2025.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Assets Average stood at $207.0 million in 2021, then skyrocketed by 33.45% to $276.2 million in 2022, then fell by 12.81% to $240.9 million in 2023, then rose by 18.06% to $284.4 million in 2024, then spiked by 56.13% to $343.1 million in 2025.
  • Its Assets Average stands at $343.1 million for Q3 2025, versus $320.4 million for Q2 2025 and $339.2 million for Q1 2025.